BROOKS - Brooks Lab.
📢 Recent Corporate Announcements
Brooks Laboratories Limited has provided an update regarding its associate company, Brooks Steriscience Limited (BSL), which is involved in a complex composite scheme of arrangement and amalgamation. BSL has received No-objection/No Adverse Observation Letters from both the NSE and BSE, marking a significant regulatory milestone. However, the BSL Board has decided to conduct a further review of the scheme before proceeding with the formal application to the National Company Law Tribunal (NCLT). This review is slated to be completed within the six-month validity period of the stock exchange approvals.
- BSL received No-objection letters from NSE and BSE for the proposed composite scheme of arrangement.
- The stock exchange approvals are valid for a period of 6 months from the date of issue.
- The scheme involves multiple entities including OneSource Specialty Pharma and Strides Pharma Services.
- BSL Board has opted for a further internal review before filing the NCLT application.
- The review process is expected to be finalized within the current six-month approval window.
Brooks Laboratories reported a consolidated net profit of ₹5.50 crore for Q3 FY26, marking a significant recovery from a loss of ₹2.13 crore in the previous year's corresponding quarter. This turnaround is largely attributed to a ₹5.20 crore profit contribution from its joint venture, Brooks Steriscience Limited. On a standalone basis, performance was subdued with revenue falling 19% YoY to ₹16.57 crore and net profit dropping to ₹0.30 crore. The company also faced a regulatory setback as the RoC did not approve the alteration of its Object Clause.
- Consolidated Net Profit of ₹5.50 crore in Q3 FY26 vs a loss of ₹2.13 crore in Q3 FY25
- Joint venture Brooks Steriscience contributed ₹5.20 crore to the quarterly profit
- Standalone Revenue declined 19.2% YoY to ₹16.57 crore from ₹20.52 crore
- Nine-month consolidated profit stands at ₹23.06 crore compared to a loss of ₹8.51 crore last year
- Regulatory rejection of Form MGT-14 prevents the planned alteration of the Memorandum of Association
Brooks Laboratories Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended December 31, 2025. The certificate, issued by Registrar MUFG Intime India Private Limited, confirms that the company followed all regulatory protocols regarding the dematerialization of securities. Notably, the Registrar reported that zero requests for dematerialization or rematerialization were received during this specific quarter. This is a standard administrative filing required to maintain the integrity of the company's share register.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Registrar MUFG Intime India Private Limited confirmed zero demat or remat requests were received.
- The filing ensures adherence to SEBI (Depositories and Participants) Regulations, 2018.
- Confirms that any security certificates received are mutilated and cancelled as per regulatory timelines.
Brooks Laboratories Limited has announced the closure of its trading window for designated persons effective from January 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations for the upcoming financial results for the quarter and nine months ending December 31, 2025. The trading restriction will remain in place until 48 hours after the declaration of the unaudited financial results. This is a standard regulatory procedure to prevent insider trading ahead of earnings announcements.
- Trading window closure effective from Thursday, January 1, 2026
- Pertains to financial results for the quarter and nine months ending December 31, 2025
- Restriction applies to all Designated Persons and their immediate relatives
- Window to reopen 48 hours after the official declaration of results
Financial Performance
Revenue Growth by Segment
The company operates in two segments: Manufacturing and Trading. For the half-year ended September 30, 2025, Manufacturing revenue reached INR 4,652.08 Lakhs, representing approximately 95% of total segment revenue, while Trading revenue contributed INR 244.18 Lakhs. Total Operating Income (TOI) grew from INR 79.48 Cr in FY24 to INR 83.04 Cr in FY25, a growth of 4.48% YoY.
Geographic Revenue Split
Not explicitly disclosed in percentage terms; however, operations are concentrated in India with the registered office and manufacturing works located in Baddi, Himachal Pradesh, and corporate offices in Mumbai, Maharashtra.
Profitability Margins
Profitability showed significant improvement with PAT margins rising from 1.90% in FY24 to 3.68% in FY25. For H1 FY26, the company's share of profit from its joint venture, Brooks Steriscience Limited, was INR 1,267.38 Lakhs, which significantly bolsters consolidated net profitability.
EBITDA Margin
The PBILDT margin improved by 117 basis points, increasing from 4.86% in FY24 to 6.03% in FY25. This improvement was driven by better operational efficiencies and stronger supplier negotiations which lowered purchase costs.
Capital Expenditure
The company strengthened its liquidity through a successful rights issue in 2023, increasing share capital from INR 2,624.67 Lakhs to INR 2,945.72 Lakhs. Specific planned CAPEX for FY26 is not disclosed, but the focus remains on scaling the manufacturing segment.
Credit Rating & Borrowing
The long-term bank facilities rating was upgraded to CARE BB; Stable from CARE BB-; Stable in November 2025. Short-term facilities are rated CARE A4. Total rated bank facilities amount to INR 12.00 Cr (INR 7.80 Cr long-term and INR 4.20 Cr short-term).
Operational Drivers
Raw Materials
Pharmaceutical ingredients and chemicals required for manufacturing formulations; specific chemical names are not disclosed, but they represent a significant portion of the manufacturing cost base.
Key Suppliers
Not specifically named; however, the company noted that 'stronger supplier negotiations' are expected to drive higher profit margins in FY26 by reducing procurement costs.
Capacity Expansion
Current manufacturing operations are based in Baddi, HP. While specific MTPA capacity is not disclosed, the company is targeting a scale-up to reach a TOI of ~INR 100.00 Cr in FY26, implying increased utilization or capacity debottlenecking.
Raw Material Costs
Raw material costs are a primary driver of the 6.03% PBILDT margin. Management's strategy to improve margins relies on reducing these costs through bulk procurement and better credit terms with vendors.
Manufacturing Efficiency
Efficiency is reflected in the improvement of PBILDT margins from 4.86% to 6.03%. The company is focusing on manufacturing over trading to capture higher value-added margins.
Strategic Growth
Expected Growth Rate
20%
Growth Strategy
The company aims to achieve a TOI of INR 100 Cr in FY26 (up from INR 83 Cr) by focusing on its manufacturing segment, optimizing supplier costs to improve margins, and benefiting from the licensing income and operational scale of its Joint Venture, Brooks Steriscience Limited.
Products & Services
Pharmaceutical formulations, medicines, and licensing of pharmaceutical products/intellectual property through its joint venture.
Brand Portfolio
Brooks Laboratories, Brooks Steriscience.
New Products/Services
Licensing income from the JV (INR 3,913.14 Lakhs in H1 FY26) indicates a shift toward high-margin intellectual property and specialized pharmaceutical products.
Market Expansion
The company is leveraging its JV to expand its reach, with the JV recording revenue of INR 6,782.45 Lakhs in just six months.
Market Share & Ranking
Not disclosed; company is characterized as having a 'small scale of operations' in a competitive industry.
Strategic Alliances
Joint Venture with Brooks Steriscience Limited, where Brooks Laboratories holds a significant stake and shares 50% of the profit after tax (INR 1,267.38 Lakhs share in H1 FY26).
External Factors
Industry Trends
The pharmaceutical industry is evolving toward higher compliance standards and specialized formulations. Brooks is positioning itself by shifting focus to manufacturing and leveraging JV licensing income, which grew to represent a major portion of JV revenue (INR 3,913.14 Lakhs).
Competitive Landscape
Operates in a fragmented and highly competitive market with numerous domestic and international pharmaceutical players.
Competitive Moat
The moat is based on the 'established track record of operations' and 'experienced promoters'. However, the moat is narrow given the small scale and high competition, making the JV's performance critical for sustainability.
Macro Economic Sensitivity
Sensitive to healthcare spending and pharmaceutical regulatory policies in India.
Consumer Behavior
Increased demand for quality pharmaceutical formulations and specialized medicines.
Geopolitical Risks
Potential trade barriers or regulatory changes affecting pharmaceutical exports or raw material imports from global suppliers.
Regulatory & Governance
Industry Regulations
Subject to stringent pharmaceutical manufacturing standards and periodic inspections. The company must comply with Ind AS 108 for segment reporting and other statutory requirements under the Companies Act 2013.
Taxation Policy Impact
The company has not recognized deferred tax assets on business losses/depreciation due to a lack of 'reasonable certainty of taxable profit', indicating a conservative but cautious tax position.
Legal Contingencies
The Auditor's Report (CARO 2024-25) noted qualifications/adverse remarks under Clause 3(ii)(b) and 3(vii)(b) for the holding company, and several clauses for the JV, indicating some areas of regulatory or internal control friction.
Risk Analysis
Key Uncertainties
The primary uncertainty is the 'absence of reasonable certainty of taxable profit', which prevents the recognition of deferred tax assets. Additionally, the reliance on the JV for a significant portion of consolidated profits (INR 12.67 Cr in H1 FY26) creates a dependency risk.
Geographic Concentration Risk
High concentration in Baddi, Himachal Pradesh for manufacturing operations.
Third Party Dependencies
High dependency on the performance of the Jointly Controlled Entity, Brooks Steriscience Limited, for consolidated bottom-line growth.
Technology Obsolescence Risk
The company is maintaining an 'audit trail' feature in its accounting software since April 2023 to comply with new regulations, showing a commitment to digital compliance.
Credit & Counterparty Risk
Trade payables stood at INR 1,362.43 Lakhs (Consolidated) as of March 31, 2025, reflecting ongoing working capital management requirements.